Prevention of Delayed Graft Function in Kidney Transplant Recipients through a Continuous Infusion of the...

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Delayed graft function (DGF) is a frequent complication following deceased-donor kidney transplantation.
• DGF can negatively impact short-term and long-term kidney transplant outcomes.
• Identifying strategies to mitigate DGF is crucial for improving transplant success.

Purpose of the Study:

• To investigate the efficacy of intravenous iloprost in reducing DGF incidence after deceased-donor kidney transplantation.
• To assess the safety and effectiveness of iloprost in the peri-transplant period.
• To evaluate the impact of iloprost on DGF duration and graft outcomes.

Main Methods:

• Prospective, randomized, placebo-controlled trial (1:1 ratio).
• Enrolled patients receiving deceased-donor kidney transplants between January 2000 and December 2012.
• Treatment group received continuous iloprost infusion (0.27 μg/min); control group received a placebo.

Main Results:

• Multivariate analysis identified donor age > 70, cold ischemia time > 24h, donor acute kidney injury, and recipient hypotension as significant risk factors for DGF.
• Iloprost significantly reduced DGF incidence (21.4% vs. 50.9%, p < 0.001).
• Patients receiving iloprost who developed DGF experienced a shorter duration of DGF (10.5 vs. 13.4 days, p = 0.016).

Conclusions:

• Continuous iloprost infusion is a safe and effective strategy to decrease DGF incidence in recipients of deceased-donor kidneys.
• Iloprost administration can lead to improved graft function and enhanced graft survival post-transplantation.
• This approach offers a promising method for optimizing outcomes in kidney transplant recipients at risk for DGF.